Frontlight ResearchEarly access
Active, not recruitingPhase 3
A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy
Key facts
- Who runs it
- Hoffmann-La Roche
- Where
- Altamonte Springs, Aurora, Dallas, Detroit, Iowa City, New York, Rochester, and San Francisco, United StatesSee the 8 sitesAlso in 10 other countries, 42 sites
- Status
- Active, not recruiting
- Phase
- Phase 3
- People taking part
- 142 people enrolled
- Started
- 25 Jun 2021
- Expected to end
- 21 Dec 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Obinutuzumab
- Tacrolimus
- Methylprednisolone
- Acetaminophen
- Diphenhydramine
- Record updated
- 1 October 2026
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Diagnosis of primary membranous nephropathy (pMN) according to renal biopsy prior to or during screening
- Screening urinary protein-to-creatinine ratio (UPCR) >= 5 g/g from 24-hour urine collection after best supportive care for >= 3 months prior to screening or screening UPCR >= 4 g/g after best supportive care for >= 6 months prior to screening
- eGFR >= 40 mL/min/1.73m\^2 or qualified endogenous creatinine clearance >= 40 mL/min/1.73m\^2 based on 24-hour urine collection during screening
- Other inclusion criteria may apply
Who cannot take part
- Evidence of >= 50% reduction in proteinuria during the previous 6 months prior to randomization
- Receipt of an excluded therapy, including any anti-CD20 therapy less than 9 months prior to or during screening; or cyclophosphamide, tacrolimus, or cyclosporin less than 6 months prior to or during screening
- Major surgery requiring hospitalization within the 4 weeks prior to screening
- Current active alcohol or drug abuse or history of alcohol or drug abuse within 12 months prior to screening
- Intolerance or contraindication to study therapies
- Severe renal impairment, including the need for dialysis or renal replacement therapy
- Type 1 or 2 diabetes mellitus
- Significant or uncontrolled medical disease which, in the investigator's opinion, would preclude participant participation
- Known active infection of any kind or recent major episode of infection
- Participants with a secondary cause of MN
- Pregnancy or breastfeeding
- Other exclusion criteria may apply
Where in United States
Also in 10 other countries, 42 sites
- Accel Research Sites; Mid-Florida Kidney and Hypertension CareAltamonte Springs, United States
- University of Colorado in Denver-Anschutz Medical CampusAurora, United States
- Nephrotex Research GroupDallas, United States
- Henry Ford HospitalDetroit, United States
- University of IowaIowa City, United States
- Columbia University Medical CenterNew York, United States
- Mayo ClinicRochester, United States
- Kaiser Permanente San Francisco Medical CenterSan Francisco, United States
About the trial
What the trial wants to find out
This study will evaluate the efficacy, safety, pharmacodynamics, and pharmacokinetics (PK) of obinutuzumab compared with tacrolimus in participants with primary membranous nephropathy (pMN).
The 2 groups in the trial
- Open Label Treatment: ObinutuzumabTreatment being tested
Participants will be randomized at a 1:1 ratio to receive open-label treatment with obinutuzumab according to region and anti-phospholipase A2 receptor (PLA2R) autoantibody titer (using Euroimmun ELISA).
Treatment: Obinutuzumab, Methylprednisolone, Acetaminophen, and Diphenhydramine
- Open Label Treatment: TacrolimusExisting treatment, for comparison
Participants will be randomized at a 1:1 ratio to receive open-label treatment with tacrolimus according to region and anti-PLA2R autoantibody titer (using Euroimmun ELISA).
Treatment: Tacrolimus
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Phase III Randomized, Open-Label Active Comparator-Controlled Multicenter Study to Evaluate Efficacy and Safety of Obinutuzumab in Patients With Primary Membranous Nephropathy
- Publications
- Obinutuzumab or Tacrolimus in Primary Membranous Nephropathy.The New England journal of medicine, 2026
- Obinutuzumab in Frequently Relapsing and Steroid-Dependent Nephrotic Syndrome in Children.Clinical journal of the American Society of Nephrology : CJASN, 2023
- Record updated
- 1 October 2026